China’s Central Government Unveils Final Policy for Drug and Device Regulatory Reform

by Ropes & Gray LLP

Ropes & Gray LLP

Based on the CFDA’s policy proposals published in May 2017, China’s central government announced its final policy for drug and device regulatory reform on October 8, 2017 (“Final Policy”). The Final Policy reiterates the importance of creating an innovative-conducive regulatory system and incorporates the CFDA’s main proposals to deregulate the conduct of clinical studies, to accelerate drug and device approvals, and to reinforce the responsibility of Marketing Authorization Holders.

In addition, the Final Policy attempts to strike a balance between the potentially conflicting interest of innovative and generic drug manufacturers. For example, the Final Policy modifies certain initiatives concerning the exclusivity entitlement of innovative drugs in the CFDA’s draft. Compared with the CFDA’s proposals, the Final Policy removes procedural details of the patent linkage system and the specific number of years of regulatory data protection for eligible drugs. The Final Policy seems to have intentionally left these details for further elaboration in the implementing measures to be issued by the CFDA and other related government authorities, e.g., the State IP Office.

Last but not least, the Final Policy introduces a few new initiatives that were not included in the original CFDA’s proposals. It announces a pilot program to grant compensatory patent term extensions to selective new drugs under defined conditions. Meanwhile, it also calls for the CFDA’s actions to promote early launch of generic drugs, biosimilars, and follow-on drug-device combination products to improve accessibility and reduce the health care burden.

Highlights of the Final Policy include the following:

  1. Deregulating the conduct of clinical studies: The Final Policy upholds the CFDA’s proposal to simplify the qualification process for clinical study sites and the ethics committee approval process. According to the Final Policy, companies need to secure the relevant ethics committee approvals before applying for the Clinical Trial Authorization. Nevertheless, the Final Policy neither explicitly sets a time limit for the Clinical Trial Authorization process (a time limit of 60 working days was previously provided in the CFDA’s proposals), nor explicitly allows foreign companies to conduct Phase 1 studies in China.
  2. Accelerating the drug and device approval process: The Final Policy upholds the CFDA’s proposal for conditional approvals for urgently needed therapies and orphan drugs, as well as market access benefits for new drugs. A rare disease catalogue and a rare disease patient registration system will be set up, and applicants of new products treating rare diseases may be eligible for reduced trials. Innovative drugs and devices funded by China’s national R&D research grants will be eligible for priority reviews.
  3. Promoting drug innovation and the growth of generics: The Final Policy re-affirms the CFDA’s proposals to establish a patent linkage system and to enhance regulatory data protection. However, the Final Policy removes the procedural details pertaining to both mechanisms. Generic manufacturers are required to notify patent holders of their applications for marketing authorizations in order to allow their timely filing of patent litigation claims. The CFDA/CDE’s review of the generic applications does not automatically stay during the patent disputes. China’s unique patent linkage system may not be able to sufficiently protect patent holders in its implementation, because the China Orange Book has not been formally announced, and follow-on applicants will not be motivated to voluntarily notify the parent holders.
  4. Strengthening the administration and supervision throughout product life cycles: The Marketing Authorization Holder system will be rolled out nationwide for both drugs and devices, allowing research-focused individuals and organizations to become license holders. However, the Marketing Authorization Holders will be held ultimately responsible for pre-approval and post-approval compliance obligations, as well as for the activities of their contracted research organizations, manufacturers and distributors. The CFDA and local FDAs will continue to ensure GCP, GMP, and GSP compliance through rigorous inspections. The Marketing Authorization Holders also need to register their medical representatives with local FDAs in order to detail physicians.
  5. Enhancing technical review infrastructure: The Final Policy upholds the CFDA’s proposal for a multi-disciplinary technical review system and reinforces the CFDA and Center for Drug Evaluation (“CDE”) officials’ confidentiality undertakings during the technical review process. Technical review conclusions will be made public for transparency and better oversight (except for company confidential information). The Final Policy accepts the CFDA’s proposals for allowing CTA applicants’ pre-submission consultation meetings with the CDE, but it removes procedural details therefrom. It also declares that the authority for technical reviews concerning Class 2 medical devices will be gradually consolidated by the Center for Medical Device Evaluation.

The Final Policy will likely reshape the competitive dynamics in China’s life sciences industry. R&D-based pharmaceutical and medical device manufacturers should carefully study the Final Policy, monitor the follow-on implementation measures to be issued, and analyze their impacts on business operations in China.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Ropes & Gray LLP | Attorney Advertising

Written by:

Ropes & Gray LLP

Ropes & Gray LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.